Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP3 | P08254 | 9/20 | 0.42 |
| ▸ | MMP1 | P03956 | 1/20 | 0.42 |
| ▸ | MMP9 | P14780 | 1/20 | 0.42 |
| ▸ | MMP8 | P22894 | 1/20 | 0.42 |
| ▸ | MMP2 | P08253 | 14/20 | 0.41 |
| ▸ | HTR1A | P08908 | 3/20 | 0.39 |
| ▸ | HTR7 | P34969 | 3/20 | 0.39 |
| ▸ | F13A1 | P00488 | 1/20 | 0.39 |
| ▸ | TGM2 | P21980 | 1/20 | 0.39 |
| ▸ | TGM1 | P22735 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4883757 | 0.87 | MMP3 (0.48) | MMP3MMP1MMP9MMP2 | |
| SCHEMBL4885197 | 0.87 | MMP2 (0.44) | MMP3MMP1MMP2HTR1AHTR7 | |
| SCHEMBL4885026 | 0.84 | MMP13 (0.42) | MMP3MMP1MMP2HTR1AHTR7 | |
| SCHEMBL4876342 | 0.74 | MMP2 (0.63) | MMP3MMP1MMP9MMP8MMP2 | |
| SCHEMBL4884939 | 0.74 | MMP3 (0.52) | MMP3MMP1MMP9MMP2 | |
| SCHEMBL4886950 | 0.73 | MMP13 (0.48) | HTR1AHTR7 | |
| SCHEMBL6298283 | 0.72 | MMP3 (0.49) | MMP3MMP1MMP9MMP8MMP2 | |
| SCHEMBL4885918 | 0.72 | MMP2 (0.59) | MMP3MMP1MMP9MMP8MMP2 | |
| SCHEMBL8101473 | 0.71 | MMP2 (0.65) | MMP3MMP1MMP9MMP8MMP2 | |
| SCHEMBL5494014 | 0.69 | MMP1 (0.44) | MMP3MMP1MMP9MMP8MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080234333-A1 | Novel Hydroxamic Acid Derivative as Peptide Deformylase Inhibitor and Manufacturing Method Thereof | KANG JAE-HOON | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234333-A1 | Novel Hydroxamic Acid Derivative as Peptide Deformylase Inhibitor and Manufacturing Method Thereof | PDF, PEPD, DHPS | MMP3 362/4885MMP1 885/4885MMP9 639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.